BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp. has announced promising preclinical results for its innovative breast and prostate cancer treatments, Bria-OTS+™ and Bria-PROS+™, showing effective anti-cancer immune responses. These next-generation immunotherapies, which are designed to be ready-to-use and personalized, have demonstrated the potential to activate multiple immune system components, offering hope for durable cancer treatment with a favorable safety profile. BriaCell anticipates moving these treatments into phase 1/2a clinical trials, aiming to provide significant clinical efficacy and survival benefits to patients.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
